Insofar as the STOP-HE results imply that dosing should be higher, OCRX will have to reexamine the dosing for the oral formulation. Other than that, there are no changes planned for the oral program at this time.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.